👥 Who does #REGUARD include? Patients with advanced or metastatic renal cell carcinoma treated with systemic therapy at GUARD centers, covering first and subsequent treatment lines. ---- 👥 ¿A quién incluye #REGUARD? Pacientes con carcinoma renal avanzado o metastásico tratados con terapia sistémica en centros GUARD, incluyendo la primera línea y las líneas posteriores. #CarcinomaRenal #RealWorldEvidence #GUARDConsortium #RenalCellCarcinoma @JaviMolinaC @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1

🧩 #REGUARD study design: • Observational • Multicenter • Retrospective inclusion from 2018 • Follow-up until death or study end • Around 500 patients expected ---- 🧩 Diseño de #REGUARD: • Observacional • Multicéntrico • Inclusión retrospectiva desde 2018 • Seguimiento hasta el fallecimiento o el final del estudio • Alrededor de 500 pacientes previstos #RealWorldEvidence #CarcinomaRenal #GUARDConsortium #RealWorldEvidence #RenalCellCarcinoma @JaviMolinaC @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1

Bladder Cancer Grand Rounds happening in Madrid! 🇪🇸 Two sessions bringing the latest evidence and worldwide clinical experience together at OncoDaily Grand Rounds during ESMO 2026. Part 1, chaired by Prof. @AndreaNecchi, featured educational lectures on: • Radical cystectomy and bladder preservation — Dr. @DrFelixGuerrero • Systemic therapy advances in localised bladder cancer — Prof. @AndreaNecchi • Treatment selection and sequencing in advanced urothelial carcinoma — Dr. Sara Coca Membribes (@scocmem) • Practical management, toxicity and monitoring — Dr. María José Juan Fita Part 2, chaired by Dr. María José Juan Fita, brought worldwide experience to the discussion through shared clinical cases. The panel explored the use of enfortumab vedotin plus pembrolizumab, perioperative strategies, treatment sequencing and bladder preservation and how access and reimbursement shape everyday decisions. Joining the discussion were Dr. Sara Coca Membribes (@scocmem) (United Kingdom), Dr. @DrFelixGuerrero (Spain), Dr. Helena Kremer (Brazil), Dr. Kelvin Yan (Hong Kong, China), Dr. @DrUddiGoswami (India), Dr. Samvel Bardakhchyan (Armenia), Dr. Lazar Popovic (@LazarPo31787807) (Serbia), Prof. Chunguang Yang (China), Dr. Javier Molina Cerrillo (@JaviMolinaC) (Spain) and Dr. Kleida Mati (Albania). The same clinical scenario can lead to very different treatment choices across countries. Sharing these experiences helps us understand the gaps and what we can do better together. Thank you to all our faculty and participants for such an open and engaging discussion! This independent educational activity is supported by a grant from @AstellasUS. #OncoDaily #ESMO2026

Next up in the OncoDaily Grand Rounds at ESMO 2026: Bladder Cancer Edition Sara Coca Membribes (@scocmem) presenting on whether there is an optimal duration of ADC and ICI therapy, which biomarkers are needed, and whether combination, rechallenge, or sequencing strategies work.

The Bladder Cancer Edition at ESMO26 has come to a close! Thank you to our speakers and everyone who joined us for insightful discussions on recent advances and future directions in bladder cancer care. @DrFelixGuerrero @DrUddiGoswami @JaviMolinaC

Bladder Cancer Edition during ESMO26 panel discussion right now real world scenarios gaps in treatment access role of mdt and physician consensus finding the optimal option for patients from different socioeconomic backgrounds. @DrFelixGuerrero @DrUddiGoswami @JaviMolinaC

🎯 The objective of #REGUARD is to generate real-world evidence on the management of advanced renal cell carcinoma across GUARD centers and throughout successive treatment lines. A national longitudinal registry to better understand clinical practice. ---- 🎯 El objetivo de #REGUARD es generar evidencia en vida real sobre el manejo del carcinoma renal avanzado en los centros GUARD y a lo largo de las sucesivas líneas de tratamiento. Un registro longitudinal nacional para conocer mejor la práctica clínica. #CarcinomaRenal #InvestigaciónClínica #GUARDConsortium #RenalCellCarcinoma #ClinicalResearch  @JaviMolinaC @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1

📊 Renal cell carcinoma accounts for around 2–3% of adult malignancies. In Spain, about 7,000 new cases are diagnosed each year, and 25–30% present with metastatic disease at diagnosis. #REGUARD will help describe its real-world management. ----- 📊 El carcinoma renal representa alrededor del 2–3% de los tumores malignos en adultos. En España se diagnostican unos 7.000 casos al año y el 25–30% presenta enfermedad metastásica al diagnóstico. #REGUARD ayudará a describir su manejo en práctica clínica real. #CarcinomaRenal #RealWorldEvidence #RenalCellCarcinoma  @JaviMolinaC @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1

🔬 GUARD Consortium launches #REGUARD, a multicenter registry of systemic treatment in patients with advanced renal cell carcinoma in real-world clinical practice. A project designed to generate longitudinal evidence across treatment lines. ----- 🔬 GUARD Consortium pone en marcha #REGUARD, un registro multicéntrico de tratamiento sistémico en pacientes con carcinoma renal avanzado en práctica clínica real. Un proyecto para generar evidencia longitudinal a lo largo de las distintas líneas terapéuticas. #CarcinomaRenal #RealWorldEvidence #GUARDConsortium #RenalCellCarcinoma @JaviMolinaC @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1

🎥 Dr. Javier Molina presents #REGUARD, a multicenter registry of systemic treatment in patients with advanced renal cell carcinoma in real-world clinical practice. The project aims to generate longitudinal evidence across different treatment lines and provide a better understanding of patient management and outcomes in routine clinical practice. 👉 Interested in learning more or participating in the registry? Contact GUARD Consortium. #RenalCellCarcinoma #RealWorldEvidence #ClinicalResearch #GUARDConsortium --- 🎥 El Dr. Javier Molina presenta #REGUARD, un registro multicéntrico sobre el tratamiento sistémico de pacientes con carcinoma renal avanzado en la práctica clínica real. El proyecto busca generar evidencia longitudinal a lo largo de las distintas líneas terapéuticas y conocer mejor el manejo y los resultados de los pacientes en la práctica clínica habitual. 👉 ¿Quieres conocer más detalles o participar en el registro? Contacta con GUARD Consortium. #CarcinomaRenal #EvidenciaEnVidaReal #InvestigaciónClínica #GUARDConsortium @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1 @JaviMolinaC

10 Must-Read Posts in GU Oncology This Week | October 5–11 This week’s GU oncology selection covers bladder cancer, prostate cancer, RCC, urothelial carcinoma, testicular cancer, and liquid biopsy research. Highlights include: • Perioperative treatment questions in MIBC • IDC and invasive cribriform carcinoma in prostate cancer • Triplet therapy in RCC • Olaparib plus abiraterone in non-BRCA-mutated mCRPC • Urine cfRNA profiling in bladder cancer • Testicular cancer self-exam guidance • TURBT completeness in SAKK 06/19 • TROFUSE-055 bladder surgery-sparing strategy • FGFR-altered urothelial carcinoma in the EV–pembrolizumab era • Multiplexed liquid biopsy for AR alterations in mCRPC @ruimmbernardino @JaviMolinaC @g_procopio_ @drenriquegrande @FraClaps @tompowles1 @LuigiFormisano_ Read the full article - oncodaily.com/genitourinary-… #OncoDaily #GUOncology

Is Triple Therapy Enough in Renal Cell Carcinoma? - Javier Molina Cerrillo @JaviMolinaC oncodaily.com/science/javier…

🕹️ A must read manuscript from @DrYukselUrun leadin the entire @aron_project!!!! Very happy to be part of this with dozens of friends!!! Enjoy the reading!! @MatteoSantoniMD @fmassari79 @JaviMolinaC @SoaresAndrey Global Disparities in the Availability and Reimbursement of Systemic Therapies for Renal Cell Carcinoma: Results of the International ARON-AID Survey academic.oup.com/oncolo/arti…

10 Must-Read Posts in GU Oncology This Week | Last Week of September The last week of September brought important updates across GU oncology, spanning prostate cancer, renal cell carcinoma, urothelial cancer, and non–muscle-invasive bladder cancer. This week’s selection includes updates on: • PSMA PET/CT kinetics during systemic therapy and radiotherapy in hormone-sensitive prostate cancer • Empiric triplet therapy and biomarker-selected intensification in metastatic clear-cell renal cell carcinoma • Drug–drug interactions in prostate cancer care • Belzutifan plus lenvatinib after PD-1/PD-L1 therapy in advanced RCC with a clear cell component • Adjuvant pembrolizumab after surgery for clear cell renal cell carcinoma • Enfortumab vedotin monotherapy according to age • Baseline PSMA PET/CT prognostic value in synchronous metastatic hormone-sensitive prostate cancer • Micro-ultrasound in prostate cancer • NECTIN4 RNA expression as a potential biomarker for enfortumab vedotin plus pembrolizumab in metastatic urothelial cancer • A risk model for predicting BCG-unresponsive disease or progression in high-grade Ta/T1 non–muscle-invasive bladder cancer 💡 Takeaway: These posts reflect how GU oncology continues to evolve across precision imaging, biomarker-driven treatment, treatment escalation and de-escalation, toxicity management, real-world outcomes, risk prediction, and multidisciplinary decision-making. @JGomezRivas @drenriquegrande @fazekasMD @g_procopio_ @scocmem @JaviMolinaC Read the full article - oncodaily.com/genitourinary-… #OncoDaily #GUOncology

🇪🇸 🇫🇷 Lurbinectedin + irinotecan | Phase II | GEP-NENs 👥 34 pts | 20 NECs + 14 NETs 🎯 ORR: 15% NEC | 7.1% NET ⏳ mPFS: 3.1 vs 3.4 mo 📈 mOS: 7.2 vs 16.6 mo ⚠️ G≥3 neutropenia 47.1% 💡 Activity mainly in pretreated GEP-NECs. 🔗 doi.org/10.1016/j.esmoop.202…

🟠 DIRECTO #GUARDSymposium2026 📍 Sala Rubio El Dr. Javier Molina @JaviMolinaC, la Dra. Isabel Galante y el Dr. Abrahams Ocanto @abraocantoMD lideran el taller de cáncer renal avanzado. La sesión combina presentación de proyectos, generación de nuevas líneas de trabajo y discusión científica, con un bloque dedicado al papel de la inteligencia artificial. #KidneyCancer #InteligenciaArtificial #Innovación #GUARDConsortium @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1 @Uro_Oncologist

🟠 DIRECTO #GUARDSymposium2026 en #MesadeDebate ¿Cómo optimizar el tratamiento del carcinoma renal avanzado y ampliar las opciones disponibles? El Dr. Javier Molina @JaviMolinaC aborda la secuenciación terapéutica, mientras que el Dr. Guillermo de Velasco @g_develasco analiza las nuevas dianas que pueden marcar el futuro en la mesa de cáncer renal. #KidneyCancer #RCC #Oncología #MedicinaDePrecisión #GUARDConsortium @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1 @Uro_Oncologist

🚨 DAY 2 | #GUARDSymposium2026 Coverage by OncoAlert After progression, what's the right next line—TKI, IO rechallenge, or a HIF-2a combination? The evidence isn't equal across options. 🧭 At #GUARDSymposium2026, Dr. Javier Molina 🇪🇸, Servicio de Oncología Médica, Hospital Universitario Ramón y Cajal, Madrid, walks through evidence-based sequencing for advanced #RCC—from relapse after adjuvant therapy to progression on IO-based first-line combinations—covering appropriate use of VEGFR TKIs, the limited data behind IO rechallenge, emerging HIF-2a-targeted combinations, and why clinical trial enrollment remains key to personalizing subsequent therapy. #KidneyCancer @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1 @Uro_Oncologist @Ecastromarcos @abraocantoMD @AlvarezMa89031 @scocmem @OncBrothers @Helena_de_Palma @F_lopez_campo @DrIacovelli @tompowles1 @mjuanfi81 @AndreaNecchi @Martin_AngelMD @cinthiavgauna @NicosiaMd @GiuliaMarvaso84 @ArkaitzLab @Dolmos77 @alvarojuarezs @Prof_Nick_James @Dav_Lorente @charlesryanmd @Uro_Dominguez @JaviMolinaC @g_develasco @tonivilaseca @MarioHArroyo @urbano_anido @DrRosenbergMSK @GuardConsortium

🚨 GUARD SYMPOSIUM 2026 — FREE VIRTUAL REGISTRATION FOR COLLEAGUES IN LATAM! 🌎 HAPPENING TODAY (HYBRID MEETING) 📅 September 16–18, 2026 (STARTS TODAY) 📍 Madrid, Spain | Hybrid Meeting 🔗 REGISTER HERE👉 buff.ly/7heG7rX The GUARD International Symposium 2026 will bring together a multidisciplinary international faculty to discuss the latest advances in genitourinary oncology. 🎥 Attend in person or via live streaming 🌐 Presentations in English & Spanish 🇱🇦 Special offer for colleagues from LATAM: Use the code: ONCOALERTGUARD2026 for FREE registration! Join leading experts and colleagues for three days of cutting-edge science, clinical insights, and collaboration in genitourinary oncology. #GUARDConsortium #GUOncology #Oncología #CancerResearch #UroOncology @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1 @Uro_Oncologist @Ecastromarcos @abraocantoMD @AlvarezMa89031 @scocmem @OncBrothers @Helena_de_Palma @F_lopez_campo @DrIacovelli @tompowles1 @mjuanfi81 @AndreaNecchi @Martin_AngelMD @cinthiavgauna @NicosiaMd @GiuliaMarvaso84 @ArkaitzLab @Dolmos77 @alvarojuarezs @Prof_Nick_James @Dav_Lorente @charlesryanmd @Uro_Dominguez @JaviMolinaC @g_develasco @tonivilaseca @MarioHArroyo @urbano_anido @DrRosenbergMSK @GuardConsortium

La Mesa Cáncer Renal del #GUARDSymposium2026 reunirá, bajo la moderación de la Dra. Teresa Alonso y el Dr. @dralvaropinto a: • Dr. Roberto Iacovelli @DrIacovelli — terapia adyuvante en ccRCC de alto riesgo • Dra. Andrea Luna Mass — nuevas herramientas de imagen • Dr. Javier Molina @JaviMolinaC — secuenciación en RCC avanzado • Dr. Guillermo de Velasco @g_develasco — nuevas dianas terapéuticas 📅 16–18 sept. · Madrid 🔗 guardconsortium.org/activida… @DrFelixGuerrero @cdanicas @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1 @Uro_Oncologist @BerUrologia